These Are Amazing Figures for a Company That Now Trades At Just Under $1/Share!
What’s taking shape is a rarity. It’s the birth of what could prove to be a multi-Tn industry as it expands globally. You may never again see an opportunity of this scale in your lifetime.
Here’s the bottom line. Since its founding, Allied (OTCQB: ALID) has focused exclusively on the big picture…the rise of this entirely new class of pharmacology.
What’s more, the compounds that Allied intends to produce and supply to the pharmaceutical industry cannot, to the best of my knowledge, be synthesized with current technologies to match natural sources.
All these highly complex compounds must be extracted from their botanical origins. Allied reports it can customize plant production to meet highly specific customer requirements. With this capability, Allied’s resources may never be exhausted.
In my analysis of this evolving market, I firmly believe that pharmaceutical companies will establish strong, dependable alliances with organic compounds suppliers. Allied stands to potentially win big as these alliances are formed.
“…pharma is being careful with its approach to MJ, hemp, CB and related industries. As the cann-a-bis industry advances, we’ll likely see more and more big pharma companies ink deals with cann-a-bis firms.” - Forbes
The start of this is closer than many may think. The clock is ticking…
The FDA Calls Psych-e-delic Psi-lo-cybin a ‘Breakthrough Therapy’ for Severe Depression
Psi-lo-cybin is now being hailed as the most important development yet for treatment of post-traumatic-stress-disorder (PTSD), as well as opioid addiction and chronic depression/anxiety.
Be aware that PTSD is not just a battlefield affliction. First responders, police, medical and fire personnel can face horrific circumstances in their duties. Mental health challenges have long been an issue with civilian first responders, as well as our military.
Mental health issues have also been soaring as the result of the stresses and mental trauma triggered by the CV pandemic. Depression/anxiety and drug addiction are reaching epidemic scale as a displaced, unemployed and isolated population fights to cope with the circumstances of this nationwide problem. New therapeutic uses for psi-lo-cybin could go a long way in providing relief for that suffering.
Allied Corp. has taken a leadership role in successful new PTSD therapies for Canadian and American soldiers. In 2020, Allied initiated one of the very first clinical trials for treating veterans’ PTSD using can-na-bis & CB compounds.
In addition to the Can-na-bis / CB therapies, new research reveals highly promising results from adding psi-lo-cybin to the mix. What’s emerging is the potential for a combined can-na-bis and psi-lo-cybin approach to combat PTSD. If proven, the intellectual property rights could be worth a fortune!
Allied Corp. Advances Its Intellectual Property and Pharmaceutical Development Through Provisional Patents for Treatment of PTSD
Since its founding, Allied has been laser focused on clinical research and trials that address the immediate and pressing crisis veterans face from PTSD afflictions.
Allied’s breakthroughs have pioneered effective new therapies for treating PTSD (and related anxiety disorders) using the company’s proprietary can-na-binoid compounds and psych-e-delics.
The need for these new therapies is urgent…particularly among our veterans and first responders.
The latest Annual Report from the U.S. Department of Veterans Affairs reveals that 6,345 vets committed suicide in 2018, a number that has been on the rise for over a decade.
Allied reports that these rates could be significantly reversed through the company’s uniquely developed therapies…as well as its uniquely developed can-na-binoid and psi-lo-cybin compounds!
As a result of this work, Allied now holds two provisional patents for can-na-binoids and one provisional patent for psi-lo-cybin… with more anticipated on the horizon.
This is more than a domestic issue; it’s global.
Businesswire(dot)com reports this about the urgency for FDA approval of psych-e-delic therapeutics in the treatment of anxiety disorders:
“Depression is the world’s leading cause of disability, affecting more than 300 million people worldwide. With such a broad potential impact, this [FDA] designation represents a major step forward in mental health research and for patients suffering from depression.” 
Allied intends to take a lead in the development and production of novel psi-lo-cybin- and can-na-bis-based therapies.
With multiple patents already in the works and more potentially to come, these groundbreaking developments hold major implications for Allied Corp.’s ultimate value.
Psych-e-delic pharmacology is in its infancy. When fully grown, analysts predict its market can be measured in the tens of Bn's.
On top of the progress being made in can-na-bis-based compounds, Bn's more dollars will be in play as the FDA advances approvals in the incredible curative secrets of psi-lo-cybin compounds.
Advancing action at the FDA clearly suggests that major pharmaceutical companies like Merck, Johnson & Johnson, Eli Lilly and others are quietly preparing to meet the explosive demand for psi-lo-cybin- and can-na-bis-related-CB pharmaceutical compounds.
Anticipated FDA approvals of can-na-binoid and psych-e-delic therapies could trigger soaring demand from drug manufacturers for secure supplies of Allied’s organic pharmaceutical compounds.
As the FDA begins releasing its approvals, psych-e-delics and can-na-bis-based CB compounds should rapidly accelerate to mainstream medical applications.
This could be the rocket fuel that propels Allied Corp! Breaking down the psi-lo-cybin and can-na-bis supply chain exposes this obvious opportunity.
Allied Corp. Commands a Bottleneck in the Organic Medicinal Compound Supply Chain That Holds Massive Potential
Over the coming years, Allied is fully prepared to expand its cultivation and production capacity to meet the soaring demand anticipated for can-na-bis-based organic medicinal compounds as well as naturally derived psi-lo-cybin (as legislation allows).
On the can-na-bis front, Allied has already locked in stunning cultivation and production capacity more than sufficient to meet foreseeable near- and long-term market needs.
Unlike many smaller scale producers, Allied established production on some of the most productive land in the world — Colombia, South America.